

**Original Research****Rationale and Design of the Roflumilast or Azithromycin to Prevent COPD Exacerbations Clinical Trial**

Jerry A. Krishnan, MD, PhD<sup>1</sup> Janet T. Holbrook, PhD<sup>2</sup> Elizabeth A. Sugar, PhD<sup>2</sup> Richard Albert, MD<sup>3</sup> Steve Rennard, MD<sup>4</sup> Nina Bracken, APRN<sup>1</sup> Jiaxian He, MS<sup>2</sup> Marie Bradley, PhD, MSc PH, MPharm<sup>5</sup> Kevin Coughlin, MA<sup>6</sup> Candace C. Fuller, PhD, MPH<sup>6</sup> Bradley Hammill, DrPH, MA<sup>7</sup> Elisha Malanga<sup>8</sup> Vincent M. Malanga<sup>8</sup> David Mannino, MD, MPH<sup>8</sup> Richard A. Mularski, MD, MCR, MSHS<sup>9</sup> Hugh Musick, MBA<sup>1</sup> Jean Rommes, PhD<sup>8</sup> Julie DeLisa, MA<sup>1</sup> Sengwee Toh, ScD<sup>6</sup> Robert A. Wise, MD<sup>2</sup>

<sup>1</sup>University of Illinois Chicago, Chicago, Illinois, United States

<sup>2</sup>Johns Hopkins University, Baltimore, Maryland, United States

<sup>3</sup>University of Colorado Anschutz, Aurora, Colorado, United States

<sup>4</sup>University of Nebraska Medical Center, Omaha, Nebraska, United States

<sup>5</sup>U.S. Food and Drug Administration, Silver Spring, Maryland, United States

<sup>6</sup>Harvard Pilgrim Health Care Institute, Boston, Massachusetts, United States

<sup>7</sup>Duke University, Durham, North Carolina, United States

<sup>8</sup>COPD Foundation, Miami, Florida, United States

<sup>9</sup>Kaiser Permanente Northwest, Washington, D.C., United States

***Address correspondence to:***

Jerry A. Krishnan, MD, PhD  
Mile Square Health Center  
1220 S. Wood Street  
University of Illinois Chicago  
Chicago, IL 60608  
Phone: (312) 413-0637  
Email: jakris@uic.edu

***Running Head:*** Roflumilast or Azithromycin for COPD

***Keywords:*** COPD; acute exacerbation of COPD; clinical trials; hospital readmission reduction program;

***Abbreviations:***

**Funding Support:** Research reported in this publication was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PCS-1504-30430). This project was also supported by Task Order HHSF22301011T under Master Agreement HHSF223201400030I from the U.S. Food and Drug Administration (FDA).

**Date of Acceptance:** December 19, 2025 | **Published Online Date:** January 5, 2026

**Citation:** Krishnan JA, Holbrook JT, Sugar EA, et al. Rationale and design of the roflumilast or azithromycin to prevent COPD exacerbations clinical trial. *Chronic Obstr Pulm Dis.* 2026; Published online January 5, 2026.

<https://doi.org/10.15326/jcopdf.2025.0669>

**This article has an online supplement.**

**ABSTRACT**

Chronic obstructive pulmonary disease (COPD) is a leading cause of hospitalization and death, particularly among patients with chronic bronchitis and frequent exacerbations. Results of placebo-controlled clinical trials indicate that treatment escalation with either long-term oral roflumilast or azithromycin can reduce COPD exacerbations. However, head-to-head comparative data from clinical trials are lacking, so the relative harms and benefits of these treatments are unclear. The RELIANCE (RofLumilast or Azithromycin to prevent COPD Exacerbations) study is an investigator-initiated, multicenter, randomized, pragmatic clinical trial embedded in clinical practice to evaluate the effectiveness of treatment escalation with long-term azithromycin versus roflumilast in patients with COPD and chronic bronchitis. We solicited preferences from patients, clinicians, and other stakeholders during the design and implementation phases of the study, including feedback that informed modifications related to the COVID-19 pandemic. Eligibility criteria did not require assessments outside of clinical practice, with exclusions principally for safety. The composite endpoint of first all-cause hospitalization or death served as the primary outcome. Enrollment was initially through university-affiliated Clinical Centers but was subsequently expanded to recruit patients in community-based practices who might not otherwise participate in research. We employed human-centered design principles to improve the usability of study activities from the perspective of participants, study staff, and treating clinicians. The final study design offered the option for patients with COPD and chronic bronchitis at high-risk of hospitalization or death to be remotely consented, prescribed a medication according to the randomized treatment allocation, and complete virtual follow-up study visits in a decentralized clinical trial.

## INTRODUCTION

The public health burden of COPD is substantial, most of which is due to respiratory infections or inhaled irritants that lead to airway inflammation and worsening dyspnea and cough (COPD exacerbations).(1,2,3,4) Among patients hospitalized for COPD exacerbations in the U.S., the 12-month re-hospitalization and mortality rates are about 64% and 26%, respectively.(5) Chronic bronchitis, defined as chronic cough and sputum, identifies a subgroup of people with COPD with an especially high risk of exacerbations and death.(6,7)

In patients who continue to have exacerbations despite inhaled maintenance therapy, treatment escalation with long-term oral azithromycin or oral roflumilast is recommended to reduce the risk of COPD exacerbations on the basis of placebo-controlled clinical trials.(4,8,9) Long-term (three to 12 months) use of oral azithromycin, a macrolide with immunomodulatory, anti-inflammatory, and anti-bacterial effects to prevent COPD exacerbations is an example of an evidence-based “off-label” use of an U.S. Food and Drug Administration (FDA)-approved medication.(10,11,12,13) Roflumilast, a long-acting oral selective phosphodiesterase (PDE)-4 inhibitor with anti-inflammatory effects, was approved by the FDA in 2011 as a treatment to reduce the risk of COPD exacerbations in patients with COPD associated with chronic bronchitis.(14,15,16,17) The FDA-approved indication for roflumilast is limited to patients with COPD associated with chronic bronchitis because the protective effects of roflumilast compared to placebo on exacerbations appear to be specific to this COPD subgroup.(18)

The relative harms and benefits of adding azithromycin versus roflumilast to current therapy in COPD are unclear as there are no clinical trials directly comparing the two treatments. Such

information would address clinical uncertainty among patients and clinicians about which medication to use,(19) including efforts to reduce the risk of readmissions and death in patients hospitalized with severe COPD exacerbations.(20,21) In this report, we present the design of the Patient-Centered Outcomes Research Institute (PCORI)-funded, investigator-initiated, multicenter, stakeholder-engaged, pragmatic trial (RELIANCE, RofLumilast or Azithromycin to prevent COPD Exacerbations) to evaluate the clinical effectiveness of treatment escalation with long-term azithromycin versus roflumilast in patients with COPD and chronic bronchitis.(22)

## **MATERIALS AND METHODS**

The study was approved by the Chicago Area Institutional Review Board, which served as a single IRB for most Clinical Centers. Local IRB approval was required from some Clinical Centers. The RELIANCE clinical trial (ClinicalTrials.gov Identifier: NCT04069312) was launched in February 2020.

### **A. Stakeholder engagement**

The RELIANCE clinical trial leadership engaged end-user stakeholders early in the planning phase to ensure that study results would address knowledge gaps relevant to their expressed needs. With the help of the COPD Foundation, we elicited input from patients with COPD, their caregivers, and pulmonary physicians to identify endpoints that would drive decision-making at the point of care and confirm sufficient community-level clinical equipoise to implement a randomized clinical trial.(19) Of 196 patients or caregivers, 62% indicated they would work with researchers on a study comparing roflumilast and azithromycin. There was also community-level equipoise among practicing physicians: a survey of 43 pulmonologists indicated preferences for azithromycin in 30%, roflumilast in 9%, and no preference in 60%. The study

also included a “Stakeholder Advisory Team” that met once per year to inform study design and implementation considerations ([Table 1](#)), including amendments to the study protocol to address barriers to enrollment during the COVID-19 pandemic (see below). Representatives from the Sentinel Operations Center and from the U.S. Food and Drug Administration’s Real-World Evidence (RWE) program participated as observers in RELIANCE Executive Committee ([Figure 1](#)) meetings to promote shared learning and to provide an understanding about the use of real-world data (data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources) to generate RWE.(23,24,25)

## **B. Patient population**

### Eligibility criteria

The RELIANCE clinical trial intended to recruit a representative group of patients with COPD in whom long-term azithromycin or roflumilast was clinically indicated as a treatment intensification.(4,8,9) Eligibility criteria ([Table 2](#)) were intended to select individuals with COPD at high risk of hospitalizations or death who could be treated with either medication in clinical practice, with exclusions principally for safety as specified in the FDA Prescribing Information for roflumilast and azithromycin.(10,14) In keeping with the principles of pragmatic trials, the eligibility criteria did not require assessments outside of standard clinical practice.(26) Clinical trials to date establishing the efficacy of azithromycin and roflumilast in COPD excluded patients with concomitant asthma. (11,16). While such exclusions have been customary in placebo-controlled efficacy trials to minimize heterogeneity among study participants, it is increasingly recognized that individual patients may have features of both

COPD and asthma. Patients with a physician diagnosis of both asthma and COPD were therefore eligible to participate in the RELIANCE study.

### Recruitment

The original approach to recruitment utilized university-affiliated Clinical Centers. Patients were approached by their physician in-person during an outpatient visit or during a hospitalization (recruitment embedded in clinical practice). Written informed consent was obtained in-person using IRB-approved materials by the treating physician or other study staff.

### Modification to eligibility criteria and recruitment

During the COVID-19 pandemic, in-person outpatient visits were suspended at many Clinical Centers as part of infection control precautions.(27) Telehealth was promoted as a substitute for in-person outpatient care.(28) Pulmonologists, many of whom were involved in the evaluation and management of patients with COVID-19, were unable to continue their research in COPD. In addition, the availability of hospital beds was limited due to the surge in hospitalizations for COVID-19-related respiratory complications. Various Clinical Centers also implemented severe restrictions in most research activities to focus on federal and industry-sponsored COVID-19-related research. These clinical and research restrictions slowed enrollment into the RELIANCE study.

### *Community Partner Referral Pathway*

As a result, the study protocol was amended to include a “Community Partner Referral Pathway” to engage patients and their treating physicians in community-based settings, including practices

without dedicated research staff to obtain informed consent (approved in June 2021, after 127 participants were enrolled). Engagement of patients and treating physicians in community-based practices was expected to increase the overall rate of enrollment into the study while also improving the generalizability of study results by enrolling patients in the clinical trial who might not otherwise participate in COPD research.

To be eligible to join the RELIANCE study as a Community Partner, the physician had to be referred by a RELIANCE investigator. The onboarding process included a review of materials about the RELIANCE clinical trial and the Community Partner's role in identifying and referring eligible patients to the centralized research Call Center. In the Community Partner Referral Pathway ([Figure 2](#)), a practicing physician who was considering treatment intensification for a patient and had clinical equipoise about whether to prescribe roflumilast or azithromycin could submit an online, IRB-approved Referral Form to the Call Center (see three-page [Supplement Figure](#)). In the Referral Form, the physician was asked to attest that their patient met all eligibility criteria and was interested in learning more about the RELIANCE clinical trial. Physicians were also asked to provide the patient's preferred contact information.

The Call Center then called the patient within one business day to obtain written informed consent via e-consent or via paper, as per patient preference. After obtaining informed consent, the participant was randomized, and a study physician then submitted an e-prescription to the patient's preferred pharmacy for a 30-day supply of either roflumilast or azithromycin depending on the treatment assignment. The referring physician was notified via secure email about the randomization and after the prescription is submitted to the pharmacy. The referring physician is



also sent a secure e-mail reminder to write subsequent prescriptions for the medication, as clinically indicated. The final list of Clinical Centers and physicians using the Community Partner Referral Pathway is provided in the Supplement Table.

### *Changes in eligibility criteria*

The inclusion criteria were amended to broaden the definition of hospitalization to include: (1) Hospitalization for respiratory complications from COVID-19(29) in a patient with COPD; and (2) Hospitalization through CMS' Acute Hospital Care at Home initiative. Both amendments occurred in July 2021, after 137 participants were enrolled. In June 2024, the FDA approved the use of inhaled ensifentrine, a PDE-3 and PDE-4 inhibitor, for the maintenance treatment of COPD.(30) In July 2024, use of ensifentrine was added as an exclusion criterion to avoid theoretical complications from combined use of inhaled and oral medications that both inhibit PDE-4.

### **C. Study organization (Figure 1)**

The consortium consisted of: (1) a Clinical Coordinating Center responsible for communication and contracts with all study partners, preparing progress reports to funder, and regulatory submissions to the single IRB; (2) a centralized research Call Center to conduct virtual follow-up visits and to obtain informed consent through the Community Partner Referral Pathway; (3) a Data Coordinating Center responsible for data collection forms, data management, performance reports, and statistical analysis; (4) a Communication Center to develop participant and clinician-facing study materials fit for purpose at university-affiliated sites and community-based practices; (5) a single institutional review board (IRB) through the Chicago Area Institutional

Review Board (IRB 00009693); (6) the COPD Patient-Powered Research Network led by the COPD Foundation to engage patient community to raise awareness, provide updates, solicit feedback about study activities, manage the Stakeholder Advisory Team, and host the clinical trials management software (DatStat); (7) an independent Data Safety Monitoring Board to review safety and study performance; (8) a Steering Committee that provided overall governance for the trial with voting members including representatives from Clinical Centers and the Community Partner Referral Pathway, plus leadership of the Clinical Coordinating Center, Data Coordinating Center, and COPD Patient-Powered Research Network; (9) an Executive Committee that tracked and supported implementation of study activities; and, (10) a Community Partner Engagement Committee that included representatives of the Community Partner Referral Pathway to identify approaches to engage busy clinicians in research at the point of care.

#### **D. Study treatments**

Previous clinical trials employed various regimens for azithromycin (250 mg/day,(11) 500 mg/day three times per week,(12), or 500 mg/day for 3 days during hospitalization then 250 mg every other day (13)) or roflumilast (500 mcg/day,(15,16,17) 250 mcg/day x 4 weeks, then 500 mcg/day (19)). The patient's physician could initiate treatment with any of the regimens above or with an alternative regimen that was tailored to the patient's clinical needs and preferences (e.g., starting with a lower dose or a different dosing schedule). Decision about treatment alterations after randomization were also left to the discretion of the participant's treating clinicians.

#### **E. Consent and randomization**

All patient-facing materials and tools were submitted for IRB review prior to use. Consent (in-person or remote) was obtained by the Clinical Center or by the Call Center for the Community Partner Referral Pathway. Participants were randomly assigned to receive a prescription for azithromycin or roflumilast (1:1 allocation ratio), stratified by location (one for each Clinical Center and one for the Community Partner Referral Pathway) and smoking status (current versus former). Treatment assignment was revealed after eligibility was confirmed and consent was obtained (concealed randomization). After the treatment assignment was made, the participant remained in the study until completion (see Section F) regardless of treatment adherence.

#### **F. Primary and secondary outcomes**

The primary outcome is the composite of all-cause first hospitalization or all-cause death. We selected all-cause events, rather than COPD-related events, as the primary outcome because it is difficult to attribute hospitalization or death to a particular underlying diagnosis in patients with multiple chronic conditions. Secondary outcomes include the individual components of the composite outcome and COPD-related acute care events (hospitalization, ED visit, urgent care visit). Due to comorbid conditions (e.g., heart failure), attributing acute care events to COPD may be less reliable than all-cause events. Additional secondary events include patient-reported physical function, sleep disturbance, fatigue, anxiety, and depression; adverse events; medication adherence; crossover from one study arm to the other; treatment discontinuation; and out-of-pocket costs.

#### **G. Data collection and schedule of assessments (Table 3)**

There were no required in-person visits outside of normal clinical practice. Baseline data required for enrollment and randomization were collected by the Clinical Center or by the Call

Center for participants enrolled through the Community Partner Referral Pathway. Participants had the option of completing follow-up surveys through an online Participant Portal or being contacted by the Call Center via telephone. Follow-up data for the primary outcome were collected via Participant Portal, the Call Center, and ad hoc reporting by Study Coordinators on the Investigator Portal. All calls involving the Call Center were recorded for quality assurance and training purposes using Health Insurance Portability and Accountability Act (HIPAA)-compliant telephony software (Five9, Inc., San Ramon, California) integrated into the Call Center's Voice over Internet Protocol (VoIP) system. Recordings were stored locally on a HIPAA-compliant secure server where they will be available for up to 3 years after final data analysis and publication of the primary manuscript are complete.

Participants were queried by phone or via on-line portal (per participant preference) 1 week after randomization to determine if they filled their prescription for the study treatment, and if so, the out-of-pocket cost. Participants were then queried at 3 months and 6 months after randomization during the first year of participation, and then every 6 months until a primary outcome (all-cause hospitalization or death) was observed or the study ended. The minimum study follow-up was 6 months, regardless of whether a primary outcome was observed and the maximum study follow-up was originally 36 months but subsequently increased to 72 months (see Section I, Sample Size). Study Coordinators were asked to assist in locating participants who were lost to follow-up and in ascertaining or verifying hospitalizations and death via review of electronic health records. Study Coordinators also submitted data pertaining to adverse events, all-cause hospitalization, changes to study medications, medical diagnoses, or other relevant information.

## H. Participant retention strategies

We incorporated several strategies to enhance retention. We engaged stakeholders early and continuously in the planning and implementation of the study. A patient was included on the study's Executive Committee and a Stakeholder Advisory Team with diverse perspectives was established to ensure that study activities were informed by the needs and preferences of people with the lived experience of COPD and those who care for them. Participant burden was minimized by not requiring in-person follow-up visits and collecting information via brief questionnaires (about 15 minutes). We provided participants information about the study's public website (<https://www.reliance-study.org/>), which included the perspective of patients, caregivers, and clinicians about the RELIANCE clinical trial and a description of the study team, enrollment updates, and video recordings about advances in the management of COPD. Also, participants were given a lapel pin and a certificate of appreciation, since participants often expressed pride about their contributions to a national study of COPD.

## I. Promoting usability

Usability is a concept used in human-centered design that refers to the degree to which an experience is or is not frictionless in the context of use.(31,32) The RELIANCE Communication Center employed human-centered design to improve the usability of study activities from the perspective of participants, study staff, and treating clinicians. The Communication Center was responsible for the development of participant and clinician-facing study materials, including posters, flyers, consent forms, and other communication artifacts specific to different university-affiliated and community-based practices ([Figure 3](#)). Newly enrolled sites also received a

welcome kit to orient them to the study and guide them through key messages to communicate to potential participants (Figure 4).

## **J. Statistical analysis plan**

RELIANCE employed a randomized open-label parallel group comparative effectiveness trial design to evaluate whether azithromycin was non-inferior to roflumilast in high-risk patients with COPD for prevention of hospitalizations or death.(33,34) Our choice of a non-inferiority margin of 1.2 was based on a clinical trial in COPD.(35) Secondary sensitivity analyses included per-protocol analyses (i.e., the subgroup of patients who adhere to their assigned treatment), since non-inferiority designs can be anti-conservative in cases of cross-overs or lack of adherence to study treatment. Data on protocol performance such as treatment adherence, losses to follow-up and missing data will be used to help understand and interpret differences, if any, in the results of the two methods.(36,37)

The primary outcome is the time to first all-cause hospitalization or death. Individuals without an event will be censored at the date of last contact. A Cox proportional hazards model will be used to assess whether azithromycin is non-inferior to roflumilast. If non-inferiority is achieved, then an additional test for superiority will be performed. The primary analysis will adjust for smoking status and location (stratification variables) through the inclusion of fixed and random effects, respectively.

A test of interaction will be used to assess the potential for heterogeneity of treatment effects (HTEs) based upon smoking status (current vs former). Secondary analyses will also include

adjusting for and investigating potential HTEs for key baseline characteristics including but not limited to 3 specified comparisons: a history of asthma (yes vs no), gender (male vs female) and obesity (obese vs not obese). Analysis of secondary outcomes (e.g., patient-reported adverse events, physical function, anxiety, medication adherence) by treatment group will employ negative binomial, logistic, linear, and Cox proportional hazards models for event rates, binary outcomes, continuous outcomes, and time to event outcomes, respectively. Mixed effects models will be used to examine outcomes with repeated measurements over time and to adjust for the location stratification variable. Both unadjusted and adjusted models including the stratification variables (location and smoking status) as well as clinically important risk factors (e.g., history of asthma, medication use) will be explored. Summary statistics, model estimates with confidence intervals and p-values will be used to present the findings. Analyses will be performed to assess model assumptions.

### Adherence

Adherence is based on participant self-report, consistent with clinical practice. The degree of adherence is an important factor for interpreting the results of the ITT analysis as well as serving the basis for per-protocol analyses. However, analyses relying on post-randomization variables are likely to be biased or require complex mathematical models with numerous assumptions.(38,39) Individuals will be classified according to a number of different methods (e.g., any adherence [at least one usage], minimum adherence [above a certain threshold]) for sensitivity analyses. A variety of causal inference techniques, including inverse probability weighting methods will be used to assess the impact of adherence.

### Sample Size

Non-inferiority will be achieved if the upper boundary of the two-sided 95% confidence interval for the hazard ratio (HR: azithromycin/roflumilast) is less than the non-inferiority margin based upon a Cox proportional hazards model after adjusting for the stratification variables. This is equivalent to having a one-sided type I error rate of 0.025. The planned recruitment period was 66 months with an additional 6 months of follow-up. In the original study design, we estimated that 3,200 participants would be needed to provide 92% power with a 1-sided type I error of 0.025 to establish non-inferiority based on a study-wide event rate for the primary outcome of 30% at 12 months and log-rank test with a margin of HR = 1.2 (azithromycin: roflumilast) assuming: (1) the true HR = 1, (2) the cumulative percent with an event at 1 year was 30%, (3) a follow-up period of 36 months; and (4) a 5% loss to follow-up per year (14.3% cumulatively).

Due to slower than expected enrollment during the COVID-19 pandemic, the DSMB requested a review of the feasibility of reducing the sample size based on observed event rates in May 2022. Review of pooled masked data indicated that the cumulative incidence of the first all-cause hospitalization or death at 12 months was about 60%, which was approximately twice the expected rate at the start of the study. The DSMB approved a reduction in sample size to 1,250 (934 events) and an increase of the maximum study follow-up to 72 months, which together provides 82% power with a 1-sided type I error of 0.025. Analyses were computed using R (version 4.2.3), PASS software (version 15.0.13), and SWOG Statistical tools (<https://stattools.crab.org/>).(40,41)

### Interim analyses



A single, formal, interim efficacy analysis was planned following collection of 50% of the information (i.e., 467 of the expected 934 events of all-cause hospitalization or death have been observed with the updated sample size). The trial would be stopped early only if one of the two treatments is demonstrated to be superior, i.e., it would not be stopped if the non-inferiority criteria were met. Based upon an O'Brien-Flemming type boundary, the type I error rate would be 0.00305 for the interim analysis and 0.04695 at the final analysis to maintain a global 0.05 error rate over the course of the trial for the superiority comparison.

#### **K. Risk-based monitoring**

A risk-based monitoring plan prioritized audits at points of greatest risk to data integrity and participant safety.(42) We audited the dates of the qualifying COPD-related hospitalization by requesting source documents in a random sample of 20 participants from the highest two enrolling Clinical Centers and seven community partners. We also reviewed a random sample of six recorded calls by the Call Center agents who were obtaining informed consent in two participants recruited through the Community Partner Referral Pathway and four completed follow-up visits among participants enrolled through Clinical Centers or Community Partner Referral Pathway. We also reviewed recorded calls on an ad-hoc basis when participants report suicidal ideation, had difficulty responding to questions via phone, or request withdrawal from the study. To date, we identified protocol deviations in three participants (enrolled by two different Community Partners) due to inadequate documentation of a qualifying hospitalization for COPD exacerbation in the previous 12 months; the two enrolling Community Partners reported that dates of hospitalizations at outside health systems were difficult to discern accurately in electronic health records. The three protocol deviations were reported to the single IRB and all Community Partners were retrained on study eligibility criteria. The on-line Referral

Form (see Supplement) for the Community Partner Referral Pathway was modified to include the date of the qualifying hospitalization. No other protocol deviations from this approach to risk-based monitoring have been identified as of the date of this report.

## DISCUSSION

The RELIANCE study is an investigator-initiated, stakeholder-engaged, multi-center trial to compare the effectiveness of treatment escalation with long-term roflumilast or azithromycin in patients with COPD and chronic bronchitis in clinical practice. We solicited feedback from multiple stakeholders, including patients, clinicians, administrators, and professional societies, during the design and implementation phases of the study, including modifications related to the COVID-19 pandemic. The COPD Foundation, an advocacy group representing patients with COPD, plays a central role in implementing the RELIANCE study by leading efforts to engage the patient community, manage the broader Stakeholder Advisory Team, and host the clinical trials management software. Representatives from the Sentinel Operations Center and from the FDA's RWE program also participated as observers to promote shared learning about the use of real-world data.

The original study design relied on in-person recruitment during routine patient care at university-affiliated Clinical Centers, in-person consent, and prescribing roflumilast or azithromycin according to the randomized treatment assignment. Participant burden was minimized by conducting follow-up visits remotely via an on-line portal or phone, and abstraction of electronic health records. An unconventional aspect of the study was the engagement of patients and treating physicians in community-based practices who might not

otherwise participate in research (Community Partner Referral Pathway) to increase the overall enrollment rate in the study.(43). The Community Partner Referral Pathway is also expected to improve the generalizability of the study results. The final study design offered the option for remote consent as part of a decentralized trial infrastructure to engage patients with COPD with a particularly high rate of hospitalizations and death (about 60% at 1 year).(44) Results of the RELIANCE clinical trial are expected to be relevant to clinicians, payers, and policy makers seeking actionable evidence in COPD from trials embedded in clinical practice.(45)

## ACKNOWLEDGEMENTS

Research reported in this publication was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PCS-1504-30430). The statements in this publication are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee. This project was also supported by Task Order HHSF22301011T under Master Agreement HHSF223201400030I from the US Food and Drug Administration (FDA). FDA coauthors reviewed the study protocol, statistical analysis plan, and the manuscript for scientific accuracy and clarity of presentation. Representatives of the FDA reviewed a draft of the manuscript for the presence of confidential information and accuracy regarding the statement of any FDA policy. The views expressed are those of the authors and not necessarily those of the FDA. We also thank members of the independent data and safety monitoring board (A. Sonia Buist, MD, Chair; Donald P. Tashkin, MD; Debra Sellers; Margaret Bate; and Andre Rogatko, PhD), patients with COPD, as well as their caregivers and clinicians, and all study volunteers who served as participants.

## REFERENCES

1. Boers E, Barrett M, Su JG, Benjafield AV, Sinha S, Kaye L, Zar HJ, Vuong V, Tellez D, Gondalia R, Rice MB, Nunez CM, Wedzicha JA, Malhotra A. Global Burden of Chronic Obstructive Pulmonary Disease Through 2050. *JAMA Netw Open*. 2023 Dec 1;6(12):e2346598. doi: 10.1001/jamanetworkopen.2023.46598. PMID: 38060225; PMCID: PMC10704283.
2. US Centers for Disease Control and Prevention. COPD. [https://www.cdc.gov/cdi/indicator-definitions/chronic-obstructive-pulmonary-disease.html#:~:text=Summary-,In%202021%2C%20more%20than%2015%20million%20Americans%20\(6.4%25\)%20reported,None.\(accessed 9 July 2025\).](https://www.cdc.gov/cdi/indicator-definitions/chronic-obstructive-pulmonary-disease.html#:~:text=Summary-,In%202021%2C%20more%20than%2015%20million%20Americans%20(6.4%25)%20reported,None.(accessed%209%20July%202025).)
3. Mannino DM, Roberts MH, Mapel DW, Zhang Q, Lunacsek O, Grabich S, van Stiphout J, Meadors BL, Feigler N, Pollack MF. National and Local Direct Medical Cost Burden of COPD in the United States From 2016 to 2019 and Projections Through 2029. *Chest*. 2024 May;165(5):1093-1106. doi: 10.1016/j.chest.2023.11.040. Epub 2023 Nov 30. PMID: 38042365.
4. Global Initiative for Chronic Obstructive Lung Disease, 2025 Report. <https://goldcopd.org/2025-gold-report/> (accessed 9 July 2025).
5. Lindenauer PK, Dharmarajan K, Qin L, Lin Z, Gershon AS, Krumholz HM. Risk Trajectories of Readmission and Death in the First Year after Hospitalization for Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 2018 Apr 15;197(8):1009-1017. doi: 10.1164/rccm.201709-1852OC. PMID: 29206052; PMCID: PMC5909167.
6. Kim V, Criner GJ. The chronic bronchitis phenotype in chronic obstructive pulmonary disease: features and implications. *Curr Opin Pulm Med*. 2015 Mar;21(2):133-41. doi: 10.1097/MCP.000000000000145. PMID: 25575367; PMCID: PMC4373868.
7. Lahousse L, Seys LJM, Joos GF, Franco OH, Stricker BH, Brusselle GG. Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease. *Eur Respir J*. 2017 Aug 10;50(2):1602470. doi: 10.1183/13993003.02470-2016. PMID: 28798087; PMCID: PMC5593375.
8. Bourbeau J, Bhutani M, Hernandez P, Aaron SD, Beauchesne MF, Kermelley SB, D'Urzo A, Lal A, Maltais F, Marciniuk JD, Mulpuru S, Penz E, Sin DD, Van Dam A, Wald J, Walker BL, Marciniuk DD. 2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients With Stable COPD. *Chest*. 2023 Nov;164(5):1159-1183. doi: 10.1016/j.chest.2023.08.014. Epub 2023 Sep 9. PMID: 37690008.
9. Wedzicha JA, Calverley PMA, Albert RK, Anzueto A, Criner GJ, Hurst JR, Miravittles M, Papi A, Rabe KF, Rigau D, Sliwinski P, Tonia T, Vestbo J, Wilson KC, Krishnan JA. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. *Eur Respir J*. 2017 Sep 9;50(3).
10. Zithromax (azithromycin) prescribing information 2002, NDA 050784. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&AppINo=050784> (accessed 9 July 2025).

11. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. *N Engl J Med*. 2011 Aug 25;365(8):689-98.
12. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, Pelle AJ, Hoogsteden HC, Aerts JG, van der Eerden MM. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. *Lancet Respir Med*. 2014 May; 2(5):361-8.
13. Vermeersch K, Gabrovská M, Aumann J, Demedts IK, Corhay JL, Marchand E, Slabbynck H, Haenebalcke C, Haerens M, Hanon S, Jordens P, Peché R, Fremault A, Lauwerier T, Delporte A, Vandenberg B, Willems R, Everaerts S, Belmans A, Bogaerts K, Verleden GM, Troosters T, Ninane V, Brusselle GG, Janssens W. Azithromycin during Acute Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization (BACE). A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial. *Am J Respir Crit Care Med*. 2019 Oct 1;200(7):857-868. doi: 10.1164/rccm.201901-0094OC. PMID: 31046405.
14. Daliresp (roflumilast) prescribing information 2018, NDA 22522. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&AppINo=022522> (accessed 9 July 2025).
15. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2- 125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. *Lancet*. 2009 Aug 29;374(9691):685-94.
16. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. *Lancet*. 2015 Mar 7; 385(9971):857-66.
17. Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VK, Siddiqui S, Rekeda L, Miller CJ, Zetterstrand S, Reisner C, Rennard SI. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting  $\beta_2$ -Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. *Am J Respir Crit Care Med*. 2016 Sep 1;194(5):559-67. doi: 10.1164/rccm.201607-1349OC. PMID: 27585384.
18. Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. *Respir Res*. 2011 Jan 27; 12:18.
19. Krishnan JA, Walsh JW, Gussin HA, Bracken NE, Malanga E, Sullivan J, Albert R, Erwin K, Holbrook J, Rennard SI, Sugar E, Wise RA. Asking patients, caregivers, and clinicians for input when designing the Roflumilast or Azithromycin to prevent COPD Exacerbations (RELIANCE) Trial (abstract). *Am J Respir Crit Care Med* 2016;193:A2671.

20. Krishnan JA, Gussin HA, Prieto-Centurion V, Sullivan JL, Zaidi F, Thomashow BM. Integrating COPD into Patient-Centered Hospital Readmissions Reduction Programs. *Chronic Obstr Pulm Dis*. 2015;2(1):70-80. doi: 10.15326/jcopdf.2.1.2014.0148. PMID: 25927076; PMCID: PMC4410712.
21. Press VG, Au DH, Bourbeau J, Dransfield MT, Gershon AS, Krishnan JA, Mularski RA, Sciurba FC, Sullivan J, Feemster LC. Reducing Chronic Obstructive Pulmonary Disease Hospital Readmissions. An Official American Thoracic Society Workshop Report. *Ann Am Thorac Soc*. 2019 Feb;16(2):161-170. doi: 10.1513/AnnalsATS.201811-755WS. PMID: 30707066; PMCID: PMC6812156.
22. National Library of Medicine. Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE). <https://clinicaltrials.gov/study/NCT04069312> (accessed 9 July 2025).
23. U.S. Food and Drug Administration. Center for Biologics Evaluation and Research & Center for Drug Evaluation and Research Real-World Evidence. <https://www.fda.gov/science-research/real-world-evidence/rwd-and-rwe-focused-demonstration-projects> (accessed 9 July 2025).
24. Brown JS, Mendelsohn AB, Nam YH, Maro JC, Cocoros NM, Rodriguez-Watson C, Lockhart CM, Platt R, Ball R, Dal Pan GJ, Toh S. The US Food and Drug Administration Sentinel System: a national resource for a learning health system. *J Am Med Inform Assoc*. 2022 Nov 14;29(12):2191-2200. doi: 10.1093/jamia/ocac153. PMID: 36094070; PMCID: PMC9667154.
25. Rahman M, Dal Pan G, Stein P, Levenson M, Kraus S, Chakravarty A, Rivera DR, Forshee R, Concato J. When can real-world data generate real-world evidence? *Pharmacoepidemiol Drug Saf*. 2024 Jan;33(1):e5715. doi: 10.1002/pds.5715. Epub 2023 Oct 19. PMID: 37855046.
26. Lieu TA, Au D, Krishnan JA, Moss M, Selker H, Harabin A, Taggart V, Connors A; Comparative Effectiveness Research in Lung Diseases Workshop Panel. Comparative effectiveness research in lung diseases and sleep disorders: recommendations from the National Heart, Lung, and Blood Institute workshop. *Am J Respir Crit Care Med*. 2011 Oct 1;184(7):848-56. doi: 10.1164/rccm.201104-0634WS. PMID: 21965016; PMCID: PMC3265273.
27. Reich P, Elward A. Infection Prevention during the Coronavirus Disease 2019 Pandemic. *Infect Dis Clin North Am*. 2022 Mar;36(1):15-37. doi: 10.1016/j.idc.2021.12.002. PMID: 35168708; PMCID: PMC8837397.
28. Sculley JA, Musick H, Krishnan JA. Telehealth in chronic obstructive pulmonary disease: before, during, and after the coronavirus disease 2019 pandemic. *Curr Opin Pulm Med*. 2022 Mar 1;28(2):93-98. doi: 10.1097/MCP.0000000000000851. PMID: 34860202; PMCID: PMC8815630.
29. Balte PP, Kim JS, Sun Y, Allen N, Angelini E, Arynchyn A, Barr RG, Blaha M, Bowler R, Carr J, Cole SA, Couper D, Demmer RT, Doyle M, Elkind M, San José Estépar R, Garcia-Bedoya O, Garudadri S, Hansel NN, Hermann EA, Hoffman EA, Humphries SM, Hunninghake GM, Kaplan R, Krishnan JA, Laine A, Lee JS, Lynch DA, Make B, Matsushita K, McKleroy W, Min YI, Naik SN, O'Connor G, O'Driscoll O, Oren E,



- Podolanczuk AJ, Post WS, Pottinger T, Regan E, Rusk A, Salvatore M, Schwartz DA, Smith B, Sotres-Alvarez D, Umans JG, Vasan RS, Washko G, Wenzel S, Woodruff P, Xanthakis V, Ortega VE, Oelsner EC. Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study. *Am J Respir Crit Care Med*. 2025 Jul;211(7):1196-1210. doi: 10.1164/rccm.202408-1656OC. PMID: 40238945; PMCID: PMC12264703.
30. Ohtuvayre (ensifentrine) prescribing information 2024, NDA 217389.  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/appletter/2024/217389Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217389Orig1s000ltr.pdf) (accessed 9 July 2025).
  31. Lyon AR, Aung T, Bruzios KE, Munson S. Human-Centered Design to Enhance Implementation and Impact in Health. *Annu Rev Public Health*. 2025 Apr;46(1):467-485. doi: 10.1146/annurev-publhealth-071823-122337. Epub 2024 Dec 10. PMID: 39656968.
  32. Sculley JA, Gerald LB, Scanzera AC, Musick H, Krishnan JA. Participation in Clinical Trials Does Not Have to Be a Lousy Experience. *Ann Am Thorac Soc*. 2024 Dec;21(12):1643-1646. doi: 10.1513/AnnalsATS.202405-512IP. PMID: 39167775.
  33. Fleming TR, Odem-Davis K, Rothmann MD, Li Shen Y. Some essential considerations in the design and conduct of non-inferiority trials. *Clin Trials*. 2011 Aug;8(4):432-9. doi: 10.1177/1740774511410994. PMID: 21835862; PMCID: PMC3312046.
  34. U.S. Department of Health and Human Services. Food and Drug Administration, 2016. Non-inferiority Clinical Trials to Establish Effectiveness: Guidance for Industry.  
<https://www.fda.gov/media/78504/download> (accessed 9 July 2025).
  35. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators. Tiotropium RespiMat inhaler and the risk of death in COPD. *N Engl J Med*. 2013 Oct 17;369(16):1491-501.
  36. Murry EJ, Hernan MA. Adherence adjustment in the Coronary Drug Project: A call for better per-protocol effect estimates in randomized trials. *Clinical Trials* 2016; 13: 372-378.
  37. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Frangakis C, Hogan JW, Molenberghs G, Murphy SA, Neaton JD, Rotnitzky A, Scharfstein D, Shih WJ, Siegel JP, Stern H. The prevention and treatment of missing data in clinical trials. *N Engl J Med*. 2012 Oct 4;367(14):1355-60. doi: 10.1056/NEJMs1203730. PMID: 23034025; PMCID: PMC3771340.
  38. Murry EJ, Hernan MA. Adherence adjustment in the Coronary Drug Project: A call for better per-protocol effect estimates in randomized trials. *Clinical Trials* 2016; 13: 372-378.
  39. Wittes J. Commentary on Murray and Hernán. *Clin Trials*. 2016 Aug;13(4):379-81. doi: 10.1177/1740774516634336. Epub 2016 Mar 4. PMID: 26944312.
  40. NCSS Statistical Software. <http://www.ncss.com/software/pass/> (accessed 9 July 2025).
  41. SWOG Statistical Center. <https://stattools.crab.org> (accessed 9 July 2025).



42. US Food and Drug Administration. Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring. Guidance for industry. August 2013.  
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oversight-clinical-investigations-risk-based-approach-monitoring> (accessed 9 July 2025)
43. Krishnan JA, Duchene B, Green O. (May 21, 2024). C2. Decentralized clinical trials: Easier for patients and pulmonologists [Conference presentation]. American Thoracic Society International Conference 2024, San Diego, CA, United States.
44. US Food and Drug Administration. Conducting clinical trials with decentralized elements. Guidance for industry, investigators, and other interested parties. September 2024. <https://www.fda.gov/media/167696/download> (accessed 9 July 2025).
45. US Food and Drug Administration. Streamlined Trials Embedded in clinical Practice (STEP) Demonstration Project. CDER Center for Clinical Trial Innovation (C3TI). <https://www.fda.gov/about-fda/cder-center-clinical-trial-innovation-c3ti/streamlined-trials-embedded-clinical-practice-step-demonstration-project> (accessed 9 July 2025).

**Table 1. Members of the Stakeholder Advisory Team**

Susan Bleasdale, MD	Infectious Disease physician, and Chief Quality Officer, University of Maryland Medical System
Laura Bullock, PharmD	Pharmacist Specialist, The University of Tennessee Medical Center
Judy Corn	Director, Patient Services, American Thoracic Society
Marilynn Hyatt	Caregiver of a patient with COPD
Patricia Jellen, MSN, RN	Registered Nurse and Practice Administrator, New York Presbyterian Hospital
John Linnell	Patient with COPD
Elisha Malanga, Chair	Chief, Corporate Relations, COPD Foundation
Daniel Ouellette, MD	Chief of the Division of Pulmonary/Critical Care Medicine, Henry Ford Hospital
Susan Rappaport, MPH	Chief Scientific Officer (Retired), American Lung Association
Mariana Ramirez, LCSW	Community engagement for Hispanic populations, JUNTOS Center for Advancing Latino Health at the University of Kansas Medical Center
Wilson Quezada, MD	Pulmonary Physician, Columbia University Irving Medical Center
Allison Lambert, MD, MHS	Pulmonary Physician, Providence Medical Research Center

**Footer for Table 1:** A diverse group of stakeholders, including patients, caregivers, clinicians, administrators, and representatives of professional societies contributed to the design and implementation of the RELIANCE study.

**Table 2. Eligibility criteria, with modifications after the start of enrollment**

	Modifications
<p><b>Inclusion criteria (all of the criteria below):</b></p> <ol style="list-style-type: none"> <li>1. Patient and treating clinician considering treatment intensification with roflumilast or azithromycin to reduce the risk of COPD exacerbations;</li> <li>2. Age <math>\geq 40</math> years;</li> <li>3. Current or past smoker of at least 10 pack-years;</li> <li>4. Diagnosis by treating clinician of severe COPD and associated chronic bronchitis;</li> <li>5. Hospitalized<sup>a</sup> with a diagnosis of COPD exacerbation in the past 12 months or hospitalized<sup>b</sup> with respiratory complications associated with COVID-19<sup>b</sup> in the past 12 months;</li> <li>6. Current medications include, at a minimum, inhaled LAMA, LABA/LAMA, ICS/LABA, or ICS/LABA/LAMA; note patients prescribed or using SABA, SAMA, or SABA/SAMA on a scheduled basis (e.g., nebulized SABA/SAMA every 6 hours) are eligible since they are receiving the functional equivalent of inhaled controller therapy;</li> <li>7. English- or Spanish-speaking;</li> <li>8. Willing and able to provide a contact telephone number.</li> </ol>	<p><sup>a</sup>July 2021, modified <i>inclusion criterion #5</i> to include patients who are hospitalized at a CMS-approved hospital-at-home program to accommodate shifts in the site of care during the COVID-19 pandemic.</p> <p><sup>b</sup>July 2021, modified <i>inclusion criterion #5</i> to add respiratory complications of COVID-19.</p>
<p><b>Exclusion criteria (any of the criteria below):</b></p> <ol style="list-style-type: none"> <li>1. Unable or declines to provide informed consent;</li> <li>2. Declines to provide social security number (SSN), health insurance claims number, or Tax Payer ID Number (as applicable);</li> <li>3. History of intolerance to azithromycin or roflumilast that the patient or patient's treating clinician considers sufficiently serious to avoid either treatment option;</li> <li>4. Current treatment with long-term (more than 30 days) roflumilast, azithromycin, or ensifentrine<sup>c</sup> (previous treatment with 1 or more doses of azithromycin, roflumilast, or ensifentrine is not an exclusion criterion, as long as the patient and clinician are seeing treatment intensification options and would be willing to use azithromycin or roflumilast, as per randomized treatment assignment);</li> <li>5. Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic;</li> <li>6. History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin;</li> <li>7. Moderate to severe liver impairment (Child-Pugh B or C);</li> <li>8. Current pregnancy;</li> </ol>	<p><sup>c</sup>As of July 2024, modified <i>exclusion criterion #4</i> to exclude patients on ensifentrine to avoid theoretical complications from combined inhaled ensifentrine (a phosphodiesterase [PDE] 3 and 4 inhibitor) and oral roflumilast (a PDE-4 inhibitor).</p>

9. Any other clinician-determined exclusion as per their clinical practice.	
---	--

Pre-proof

**Table 3. Schedule of assessments**


Data item	Sources	Baseline (BL)	1 week follow-up visit	3 and 6 mos after randomization, then every 6 mos until primary outcome is recorded or 72 months after start of enrollment, whichever is first	End of study
Informed consent	Investigator Portal	X			
Demographics	Investigator Portal	X			
Smoking status	Investigator Portal	X			
	Participant Portal/Call Center			X	
PROMIS questionnaires (physical function, sleep disturbance, fatigue, anxiety, depression)	Investigator Portal	X			
	Participant Portal/Call Center		X	X	
Height, weight	Investigator Portal	X			
	Participant Portal/Call Center			X	
Study treatment (adherence, treatment discontinuation, cross- over to alternate medication)	Investigator Portal	X			
	Participant Portal/Call Center		X	X (and ad hoc)	
	Claims databases				X
Out-of-pocket costs	Participant Portal/Call Center		X	X	
Healthcare utilization	Investigator Portal	X			X
	Participant Portal/Call Center		X	X (and ad hoc)	
	Claims databases				X
Adverse events (hearing decrement, diarrhea, nausea, suicidal ideation)	Participant Portal/Call Center		X	X (and ad hoc)	
	Claims databases				X
Adverse event (microbiology cultures of macrolide resistant organisms in sputum)	Investigator Portal				X

**Footer for Table 3:** BL = Baseline; PROMIS = Patient Reported Outcomes Measurement Information System

Pre-proof

## Figure legends

**Legend for Figure 1:** Multiple groups, including university-affiliated Clinical Centers and community-based physicians (Community Partners), collaborated with a Data Coordinating Center, COPD Patient-Powered Research Network, and Clinical Coordinating Center to conduct the RELIANCE clinical trial funded by the Patient Centered Outcomes Research Institute. An Executive Committee, with representation from other functional units, tracked and supported implementation of all study activities. An independent Data Safety Monitoring Board and single Institutional Review Board provided oversight. See Section C, Study Organization, for a more details.




7.9.25

**Legend for Figure 2:** We established the Community Partner Referral Pathway to supplement the rate of enrollment from university-affiliated Clinical Centers. Each physician (“Community Partner”) receives a reminder via email or text weekly (or other frequency, as requested [Step 1])

to confirm patient eligibility and interest to join the RELIANCE clinical trial during a scheduled outpatient clinic visit [Step 2]. If the patient is eligible and interested, the physician submits a brief online referral form with their patient's contact information to the RELIANCE research Call Center using a unique Uniform Resource Locator (URL) that is specific to each Community Partner [Step 3]. After the patient's scheduled medical appointment (to avoid delays in clinic), the research Call Center calls the patient within 1 business day to assess eligibility and interest [Step 4], and to collect informed consent remotely (e-consent or mail a signed hardcopy, whichever the participant prefers; Step 5). Following randomization, a study physician at the Clinical Coordinating Center writes a prescription for the medication and sends it directly to the patient's preferred pharmacy [Step 6]. The patient's referring physician is notified of the treatment assignment and prescription information via a secure email. The research Call Center performs all follow-up visits remotely for participants enrolled through the university-affiliated Clinical Centers and the Community Partner Pathway and informs the referring physician about the information collected at each follow-up visit via a secure email [Step 7].





**Legend for Figure 3:** The recruitment materials were developed by the Communication Center using principles of human-centered design based on input from researchers, research staff, front-line clinicians, administrators, and other stakeholders. Materials included a poster that could be affixed to the wall in clinic rooms to promote interest in studying the use of roflumilast versus azithromycin (11 X 17 inches, see left), a brochure for patients to read while waiting to see their physician (2<sup>nd</sup> from left; 8.5 X 11 inches), a second smaller poster that emphasizes patient engagement in the study design (3<sup>rd</sup> from left; 8.5 X 11 inches), and a 4X 6 inch card that about the study that could be distributed to patients who wanted to learn more about the study on the website (4<sup>th</sup> from the left). Materials not shown to scale. All materials were IRB-approved prior to use.



**Legend for Figure 4:** The Welcome Kit was provided to participants in an envelope (9 X 12 inches, see left) following enrollment based on input from patients with COPD and other stakeholders. The Kit included a letter thanking the participant for joining RELIANCE (8.5 X 11

inches, 2<sup>nd</sup> from left) and a personalized certificate of appreciation that included pictures and names of call center agents and a description of planned follow-up visits (11 X 8.5 inches, 3<sup>rd</sup> from left). We also included information about follow-up visit options (8.5 X 11 inches, 4<sup>th</sup> from left). Patients with COPD often take multiple medications to treat COPD and other health conditions. Based on input from patients, the RELIANCE team also developed a summary of strategies that could be used to reduce out-of-pocket medication costs (8.5 X 11 inches, 5<sup>th</sup> from left), including requesting 90-day medication supply, asking their healthcare provider for generic alternatives, and patient assistance programs. Materials are not shown to scale. All materials were IRB-approved prior to use.



Online Supplement

**Supplement Table. RELIANCE Clinical Centers and physicians using the Community Partner Referral Pathway**

Clinical Centers (n=26)	Community Partners (n=41) nominated by Clinical Centers or members of the Executive Committee
1. Baystate Health PI: O'Neil Green, Co-I: Nicole Strieter	1. Anil Ghimire (Chronic Lung Disease Clinic - Family Health Care Network)
2. Baylor Scott & White Health – North PI: Mark Millard, Co-I Jeffrey Kopita	
3. Cleveland Clinic PI: Umur Hatipoglu	2. Randall Harris (Akron General Hospital) 3. Vickram Tejawani (Hilcrest Hospital) 4. Ian Oppenheim (Medstar Georgetown University Hospital) 5. Abhishek Bhardwaj (Coast Pulmonary & Internal Medicine Associates)
4. Duke University PI: Christopher Mosher, Co-I: Loretta Que	
5. Henry Ford Health System PI: Daniel Ouellette, Co-I: Jovica Veljanovski	6. Kevin Almerico (Miami Pulmonary Specialists)
6. Houston Methodist PI: Rodney Folz	
7. Johns Hopkins University PI: Niru Putcha, Co-I: Robert Wise	7. Michael Lester (Vanderbilt University) 8. Blake LeMaster (Vanderbilt University) 9. Adrienne Conger (Vanderbilt University) 10. Mollie Anderson (Vanderbilt University) 11. Sara Carson (Kootenai Health)
8. Kaiser Permanente Northwest PI: Richard Mularski, Co-I: Britta Torggrimson-Ojerio	12. Ben Moss (Hillsboro Medical Center)
9. Mount Sinai Health System PI: Linda Rogers	13. Wanda Choy (The Valley Hospital) 14. Alexandra Adams (UR Thompson Health Pulmonary Clinic) 15. Alissa Greenberg Lee (Connecticut Northeast Medical Pulmonary Group) 16. Dan Howell (Woodhull Hospital Brooklyn, NY)
10. NorthShore University HealthSystem PI: Shashi Bellam, Co-I: Stacy Raviv	
11. Northwell Health PI: Bushra Mina, Co-Is: Jessica Homan, Oki Ishikawa, Jennifer	
12. Northwestern University PI: Ravi Kalhan, Co-I: Sharon Rosenberg	17. Alexis Wolfe (Northwestern Lake Forest Hospital)
13. Ochsner Health New Orleans PI: Susan Gunn, Co-I: Leonardo Seoane	
14. Ohio State University	


PI: Phillip Diaz, Co-I: Sonal Pannu	
15. Temple University PI: Gerard Criner, Co-I: Nathaniel Marchetti	
16. University Hospitals Cleveland Medical Center PI: Catalina Teba	
17. University of Alabama at Birmingham PI: Surya Bhatt, Co-I: Mark T. Dransfield	
18. University of California Davis PI: Mark Avdalovic, Co-I: Brooks Kuhn	18. Brett Schaeffer (Erlanger Health System)
19. University of Illinois Chicago PI: Jerry Krishnan, Co-Is: Christie Brillante, Min Joo	19. Rodrigo Vazquez Guillamet (Washington University St. Louis) 20. Jennifer Minoff (Hannibal Regional Healthcare System) 21. Mehdi Mirsaeidi (University of Florida Health-Jacksonville)
20. University of Iowa PI: Alejandro Comellas, Co-I: Spyridon Fortis	22. Iliya Amaza (UW Health Pulmonary Clinic)
21. University of Kansas PI: Mario Castro, Co-I: Chase Hall	23. James Krings (Washington University St. Louis) 24. Dan Reynolds (Washington University St. Louis) 25. Zachary Lonjers (Washington University St. Louis)
22. University of Michigan PI: MeiLan Han, Co-I: Wassim Labaki	
23. University of Missouri – Truman Medical Center PI: Gary Salzman	26. Amine Bourbia (Harbin Clinic) 27. Gabe Anders (Bothwell Regional Health Center)
24. University of North Carolina PI: Brad Drummond	28. Jill Ohar (Wake Forest Baptist)
25. University of Pittsburgh Medical Center PI: Frank Sciurba, Co-I: Corrine Kliment	
26. University of Vermont PI: Anne Dixon, Co-I: David Kaminsky	29. Veronika Jedlovszky (Rutland Regional Medical Center, Vermont) 30. Brittany Duchene (Northeastern Vermont Regional Hospital) 31. Ram Baalachandran (Central Vermont Medical Center) 32. Suman Majumdar (Central Vermont Medical Center) 33. Facundo Stingo (Rutland Regional Medical Center)
Nominations by members of the RELIANCE Executive Committee	34. Jeannette Zinggeler Berg (Kootenai Clinic Lung & Asthma) 35. Scott Meehan (Multicare Health System) 36. Sankaran Krishnan (Boston Children's Health Physicians) 37. Catherine Hooper Miele (Virginia Mason) 38. Timothy Spooner (Centra Health) 39. Kaleb Veit (University of Nebraska) 40. Tamer Hudali (The Lung and Sleep Center of North Texas) 41. Wilfor Diaz Fernandez (Beth Israel Deaconess MC Milton)

**Footer for Supplement:** Clinical Centers and their Community Partner physicians. Some Community Partners were also nominated by members of the RELIANCE Executive Committee.

Pre-proof

## Supplemental Figure

RELIANCE patient referral



Returning?

AAA

+ -

### 1. PATIENT ELIGIBILITY

*I attest that my patient meets ALL of the following inclusion criteria:*

- a. Patient and treating clinician considering treatment intensification with roflumilast or azithromycin to reduce the risk of COPD exacerbations;
- b. Age  $\geq$  40 years;
- c. Current or past smoker of at least 10 pack years;
- d. Diagnosis of severe COPD and associated chronic bronchitis;
- e. Hospitalized with a diagnosis of COPD exacerbation in the past 12 months OR hospitalized with respiratory complications associated with COVID-19 in the past 12 months;
- f. Current medications include inhaled LAMA, ICS/LABA, or LAMA/LABA;
- g. English or Spanish speaking;
- h. Willing and able to provide a contact telephone number.

☒ Agree  
☐ Disagree  
☐ Unsure - I would like a call back from a RELIANCE clinician

---

Please enter the date of last hospitalization referenced in item e. above

08-05-2025

M-D-Y

---

### 2. I attest that my patient meets NONE of the following exclusion criteria:

- a. History of intolerance to azithromycin or roflumilast that the patient or patient's treating clinician considers sufficiently serious to avoid either treatment option;
- b. Current treatment with long-term (more than 30 days) roflumilast, azithromycin, or ensifentrine;
- c. Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic;
- d. History of cholestatic jaundice/hepatic dysfunction with prior use of azithromycin;
- e. Moderate to severe liver impairment (Child-Pugh B or C);
- f. Current pregnancy;
- g. Any other clinician-determined exclusion as per my clinical practice.

☒ Agree  
☐ Disagree



RELIANCE patient referral

☐ Unsure - I would like a call back from a RELIANCE clinician

**3. Confirmation of patient assent to be contacted:**

- ☒ I confirm that I have discussed the RELIANCE study with my patient and they would like to be contacted with further information. My patient agrees to be contacted by the Call Center.
- ☐ I confirm that I have discussed the RELIANCE study with my patient. My patient would like to contact the Call Center for further information.

**4. Please mail this patient an introductory RELIANCE kit. (This includes an envelope with a study overview, paper consent, and Call Center contact information.)**☐**5. PATIENT INFORMATION***How should the call center reach your patient?*

First name

Last name

Preferred contact phone #

Alternate contact phone # (optional)

Email address (optional)

Preferred contact method ☒ Phone ☐ Email

Preferred language ☒ English ☐ Spanish

**6. TREATING CLINICIAN INFORMATION**

Clinic name

Clinician first name

Clinician last name

Preferred contact phone #

Alternate contact phone #

Clinician email

**7. Is the information above correct?**

- ☒ Yes
- ☐ No

2/3



RELIANCE patient referral

**8. Comments***Do you have any additional comments?**For example, please include the patient's preferred days or times to be contacted by the study team.*

Patient would like to be contacted at 4pm tomorrow (Thursday).

If you have questions and would like to speak to a RELIANCE Coordinator, please call 1-833-687-2673.

If you have questions and would like to speak to a study clinician, please call 312-674-2781.

If you would like more information about RELIANCE, please visit [RELIANCE-Study.org](https://reliance-study.org) or [ClinicalTrials.org](https://clinicaltrials.org) or email [reliance@uic.edu](mailto:reliance@uic.edu).

**Submit****Save & Return Later**Powered by REDCap - [Cookie policy](#)